Personal information

Keywords

Prostate cancer, bladder cancer, pathology

Biography

Professor
Department of Pathology
UT MD Anderson Cancer Center
Houston, TX

Activities

Collapse all

Employment (1)

University of Texas MD Anderson Cancer Center: Houston, TX, US

2006-07-01 to present | Professor (Pathology)
Employment
Source: Self-asserted source
Charles C Guo

Education and qualifications (4)

Johns Hopkins Hospital: Baltimore, Maryland, US

2005-07 to 2006-06 | Genitourinary pathology fellow
Qualification
Source: Self-asserted source
Charles C Guo

New York University School of Medicine: New York, NY, US

2001 to 2005 | Pathology resident
Qualification
Source: Self-asserted source
Charles C Guo

Chinese Academy of Medical Sciences: Beijing, Beijing, CN

1990 to 1993 | graduate student (Physiology)
Qualification
Source: Self-asserted source
Charles C Guo

Qingdao University: Qingdao, Shandong, CN

1985 to 1990 | Student (Clinical Medicine)
Qualification
Source: Self-asserted source
Charles C Guo

Works (42)

A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics

2025-02-22 | Preprint
DOI: 10.1101/2025.02.17.638726
Contributors: Yishan Wang; Chenxuan Zang; Ziyi Li; Charles C. Guo; Dejian Lai; Peng Wei
Source: check_circle
Crossref

Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases

Human Pathology
2024-11 | Journal article
DOI: 10.1016/j.humpath.2024.105673
Contributors: Georges C. Tabet; Lan Zheng; Hossein Hosseini; John Ward; Louis Pisters; Matthew T. Campbell; Shi-Ming Tu; Bogdan Czerniak; Charles C. Guo
Source: check_circle
Crossref

Data from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.c.7453158
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Data from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.c.7453158.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044520
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044520.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044517
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044517.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044514
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044514.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044511.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044511
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044508
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044508.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044505
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044505.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044502.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044502
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044499
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044499.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044496
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044496.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044493.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044493
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044490
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Supplementary Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044490.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044487
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 1 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044487.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044484
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 2 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044484.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044481.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 3 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044481
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044478
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

Table 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

2024-09-17 | Preprint
DOI: 10.1158/2767-9764.27044478.v1
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

Cancer Research Communications
2024-09-01 | Journal article
DOI: 10.1158/2767-9764.CRC-24-0237
Contributors: Matthew T. Campbell; Amishi Y. Shah; Pavlos Msaouel; Nizar M. Tannir; Arlene O. Siefker-Radtke; Ashish M. Kamat; Neema Navai; Colin P.N. Dinney; Priya Rao; Charles C. Guo et al.
Source: check_circle
Crossref

TUSCAN: Tumor segmentation and classification analysis in spatial transcriptomics

2024-08-21 | Preprint
DOI: 10.1101/2024.08.20.608863
Contributors: Chenxuan Zang; Charles C. Guo; Peng Wei; Ziyi Li
Source: check_circle
Crossref

Reprint of: somatic-type malignancies in testicular germ cell tumors

Human Pathology
2023-03 | Journal article
DOI: 10.1016/j.humpath.2023.02.008
Contributors: Charles C. Guo; Bogdan Czerniak
Source: check_circle
Crossref

Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors

Journal of Clinical and Translational Pathology
2023-01-17 | Journal article
DOI: 10.14218/JCTP.2022.00029
Contributors: Charles C. Guo; Bogdan Czerniak
Source: check_circle
Crossref

Somatic-type malignancies in testicular germ cell tumors

Human Pathology
2022-09 | Journal article
DOI: 10.1016/j.humpath.2022.06.024
Contributors: Charles C. Guo; Bogdan Czerniak
Source: check_circle
Crossref

Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma

Urologic Oncology: Seminars and Original Investigations
2019-06 | Journal article
DOI: 10.1016/j.urolonc.2019.01.026
Contributors: Jonathan J. Duplisea; Firas G. Petros; Roger Li; Bryan Fellman; Charles C. Guo; Bogdan A. Czerniak; Arlene O. Siefker-Radtke; John C. Araujo; Colin P.N. Dinney; Surena F. Matin
Source: check_circle
Crossref

Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment

Human Pathology
2017-06 | Journal article
DOI: 10.1016/j.humpath.2017.01.006
Contributors: Syed Gilani; Charles C. Guo; Elsa M. Li-Ning; Curtis Pettaway; Patricia Troncoso
Source: check_circle
Crossref

Urachal carcinoma: a pathologic and clinical study of 46 cases

Human Pathology
2015-12 | Journal article
DOI: 10.1016/j.humpath.2015.07.021
Contributors: Jasreman Dhillon; Yu Liang; Ashish M. Kamat; Arlene Siefker-Radtke; Colin P. Dinney; Bogdan Czerniak; Charles C. Guo
Source: check_circle
Crossref

Peer review (6 reviews for 3 publications/grants)

Review activity for British journal of cancer. (1)
Review activity for Modern pathology. (1)
Review activity for Modern pathology. (4)
How many people are using ORCID?